Analysts JPMorgan initiated coverage of Neurogene (NGNE) with an overweight rating and a target price of $60, indicating 132% upside
JPMorgan has initiated coverage of Neurogene with an overweight rating and a price target of $60, indicating a potential 132% upside, as the company progresses on its gene therapy for Rett syndrome despite recent stock declines.